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Background: The human immunodeficiency virus (HIV) epidemic in Russia, driven by injection drug use, has seen a
steady rise in the past two decades. Hepatitis C virus (HCV) infection is highly prevalent in people who inject drugs
(PWID). The study aimed to describe the current frequency of HCV testing and treatment among HIV-infected PWID
in St. Petersburg, Russia.
Methods: This study examined baseline data from the “Linking Infectious and Narcology Care” (LINC) and “Russia
Alcohol Research Collaboration on HIV/AIDS” (Russia ARCH) studies. Participants included in this analysis were HIV-
infected with a history of injection drug use. Descriptive statistics were performed to assess frequency of HCV
testing and treatment.
Results: Participants (n = 349 [LINC], 207 [Russia ARCH]) had a mean age of 33.8 years (IQR: 31–37) in LINC and 33.0
(IQR: 30–36) in Russia ARCH; 26.6 % (LINC) and 29.0 % (Russia ARCH) were female; 100 % were Caucasian. Nearly all
participants had been tested for HCV (98.9 % in LINC, 97.1 % in Russia ARCH). Almost all reported being diagnosed
HCV positive (98.9 % in LINC, 97.1 % in Russia ARCH). Only 2.3 % of LINC and 5.0 % of Russia ARCH participants
reported ever receiving HCV treatment.
Conclusions: Among these cohorts of HIV-infected PWID in St. Petersburg, Russia, as of 2015 nearly all reported
being tested for HCV and testing positive, while only 3.3 % received any HCV treatment. In this new era of effective
HCV pharmacotherapy, an enormous chasm in the HCV treatment cascade in Russia exists providing substantial
opportunities for curing HCV in HIV-infected Russians with a history of injection drug use.
Trial registration: The studies described were registered with ClinicalTrials.gov through the National Institutes of
Health: Linking Infectious and Narcology Care in Russia (LINC) - NCT01612455, registered 1 June 2012, first participant
enrolled 3 July 2012; Alcohol’s Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort - NCT01614626,
registered 25 May 2012, first participant enrolled 15 November 2012.
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Worldwide, hepatitis C virus (HCV) infection is esti-
mated to affect 80 million people [1], placing them at
risk for liver cirrhosis, hepatocellular carcinoma, and
associated morbidity and mortality [2]. In most parts of
the world, HCV transmission occurs through parenteral
exposure, including via injection drug use (IDU) [3].
HCV is highly prevalent among people who inject drugs
(PWID) through the sharing of contaminated injection
paraphernalia [4].
Following the collapse of the former Soviet Union in
the 1990s and the Afghan war, Russia experienced
increased access to heroin and an upsurge in injection
drug use among young adults along with subsequent risk
for related viral infections [5]. Harm reduction programs
exist in Russia, but are inadequate [6]. Access to needle
exchange programs is limited and fear of law enforce-
ment leads to reluctance to carry needles. Currently, opi-
oid agonist treatments are illegal in Russia and thus
unavailable for those persons with opioid use disorders
[7, 8]. As a result, the prevalence of HIV and HCV
among Russian PWID is among the highest in the world.
It is estimated that a quarter of PWID in Russia have
HIV [9], while the vast majority have HCV [4]. A recent
study of HCV prevalence in eight Russian cities reported
that PWID in St. Petersburg had the highest prevalence
of HCV (90 %) [10]. Recent estimates of HCV preva-
lence in Russia suggest that 3–4 % of the population is
infected [1, 11–13].
With new, direct-acting HCV agents offering attain-
able sustained virologic response (SVR) or cure, under-
standing the HCV cascade of care is paramount. The
HCV cascade of care describes successive steps of
healthcare specific to HCV that result in optimal health
outcomes. Areas of the HCV cascade of care include
initial screening, confirmatory viral load testing, linkage
to care, staging of disease, initiation of therapy, and re-
ceipt and adherence to therapy [14]. Deficits along the
care continuum have been reported in numerous coun-
tries including the U.S., Canada, Australia, and India,
particularly among PWID [15–19]. Less is known about
gaps in other countries, including Russia, which has one
of the largest populations of HIV-infected PWID [20].
Given the confluence of the ongoing Russian epidemic of
HCV and HIV co-infection and the new effective HCV
treatments, we investigated care for HCV among HIV-
infected Russian PWID in St. Petersburg, Russia. Specific-
ally, we evaluated the frequency of HCV screening and
treatment, hypothesizing that screening would far exceed
treatment in this population.
Methods
This analysis is a descriptive, observational study on
self-reported HCV testing and treatment among HIV-infected Russian PWID. We analyzed data collected
from two studies in St. Petersburg, Russia: LINC and
Russia ARCH, for which study methods have been pre-
viously published [21, 22]. Linking Infectious and
Narcology Care (LINC), is a randomized controlled
trial testing a peer-led strengths-based case manage-
ment intervention to link HIV-infected PWID hospi-
talized at a narcology (addiction) hospital to HIV
medical care in St. Petersburg, Russia. Participants
were recruited from inpatient wards at the City Addic-
tion Hospital (CAH) in St. Petersburg, Russia from
July 2012 through May 2014. Russia Alcohol Research
Collaboration on HIV/AIDS (Russia ARCH) is an
observational cohort that aims to evaluate the longitu-
dinal association between alcohol consumption and
biomarkers of microbial translocation and inflamma-
tion. Participants were recruited between November
2012 and June 2015 from clinical HIV and addiction
sites, non-clinical sites and snowball sampling in St.
Petersburg, Russia. Eligibility criteria for both studies
included the following: 1) 18–70 years of age; 2) HIV-
infection; 3) having two contacts to assist with follow-
up; 4) living within 100 km of St. Petersburg and 5)
having a telephone. For LINC, additional criteria
included being hospitalized at the narcology hospital,
history of injection drug use, and not currently being
on antiretroviral therapy (ART) (prior history of ART
was not an exclusion). For Russia ARCH being ART-
naïve (i.e. never having been on ART) was an eligibility
criteria. All study participants provided informed consent
and Institutional Review Boards of Boston University
Medical Campus and First St. Petersburg Pavlov State
Medical University approved the LINC and Russia ARCH
studies.
For this analysis, the Russia ARCH sample was
limited to participants who were not previously en-
rolled in the LINC study and who were categorized
as PWID (i.e., participant reported at least one of
the following: used needles to inject drugs prior to
HIV diagnosis or past 30-day IDU). Using responses
from the baseline questionnaire, we assessed the fol-
lowing: previous testing of HCV [23], location of
HCV testing [23], date of HCV testing [23], phys-
ician reported HCV status [23], prior treatment for
HCV [23], and date of HCV treatment initiation
[23], demographics, HIV risk behaviors [24] and sub-
stance use [24–29]. Questions about HCV testing
were worded in the following manner: “Have you
ever been tested for the hepatitis C virus?”, and “Has
a doctor ever told you that you had the hepatitis C
virus?” As such, questions did not refer to the spe-
cific diagnostic test done (i.e. screening antibody or
HCV viral load). Not all questions were asked in
both surveys.
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The total sample included 556 HIV-infected Russian
adult PWID (n = 349 [LINC], 207 [Russia ARCH]).
Details of enrollment are presented in Additional file 1:
Figure S1 and Additional file 2: Figure S2. In LINC 382
potential participants were assessed, and of those, 349
were found to be eligible and were enrolled and in-
cluded in the analysis. In Russia ARCH 556 persons
were assessed, and of those 365 were found to be
eligible and 364 were enrolled. Of those, 90 were also
participants in LINC, 13 subsequently disenrolled from
the study, and 54 were not known to be injection drug
users, and were therefore excluded from this analysis,
leaving 207 in the sample. Only 1 % of persons
screened for LINC were excluded for current ART use,
and 13 % of Russia ARCH persons screened were ex-
cluded for past or current ART.
Baseline demographic and other characteristics of each
sample, and both samples combined, are shown in
Table 1. Participants in these two studies were relatively
young, the majority were men, and as is expected for
this population, all were Caucasian. The vast majority
completed secondary education, and approximately half
reported being unemployed. Median time since HIV
diagnosis was 7.1 years (IQR = 4-12), and median CD4
cell count was 349 (IQR = 201-550). All in Russia ARCH
and the vast majority in LINC were HIV ART-naïve.
Current substance use disorders were common in both
cohorts (Table 1).
Almost all HIV-infected PWID in LINC (345
[98.9 %]) and Russia ARCH (201 [97.1 %]) reported
past HCV testing; similarly nearly all participants in
LINC (345 [98.9 %]) and Russia ARCH (201 [97.1 %])
reported past physician diagnosis of HCV. In most
cases (328 [95.1 %]), the time since HCV diagnosis was
≥ 12 months in LINC. Of 345 reporting HCV testing in
LINC, testing occurred in hospitals (193 [55.9 %]), out-
patient clinics (107 [31.0 %]), and prisons (37 [10.7 %])
(Table 2). Almost all were HCV treatment-naïve in
both LINC (336 [97.4 %]) and Russia ARCH (191
[95.0 %]) (Table 3).
Among eight reporting prior HCV treatment in LINC,
7 (87.5 %) initiated treatment ≥ 12 months prior. Of 10
with prior HCV treatment in Russia ARCH, 5 (50.0 %)
reported achieving SVR and 3 (30.0 %) had unknown
outcomes (Table 3). The median age of the 8 HIV-HCV
co-infected PWID in LINC receiving HCV treatment
was 32.6 (IQR 31.15-34.4), 5 (62.5 %) were never mar-
ried, all 8 (100 %) were male, 1 (12.5 %) was working
part-time, and 5 (62.5 %) completed secondary education
or lower. Among ten Russia ARCH participants who re-
ported receiving HCV treatment, the median age was
31.5 (IQR 29-35), 4 (40 %) were married or living with a
partner, 6 (60 %) were male, 3 (30 %) were working part-time or full-time, and 9 (90 %) completed secondary
education or lower.
Discussion
This study of two St. Petersburg Russian cohorts of
HIV-infected PWID found an enormous gap between
testing and receipt of HCV treatment, revealing a
“chasm” in the hepatitis C virus (HCV) care cascade.
This study found that nearly all participants reported be-
ing screened and informed that they had been HCV-
infected, suggesting that screening efforts are robust in
this population of PWID with HIV. In contrast to nearly
ubiquitous rates of screening, few patients (LINC =
2.3 %, Russia ARCH = 5.0 %) reported ever receiving
treatment. This points to a chasm with regard to not
meeting European Association for the Study of the Liver
(EASL) guidelines for prioritizing HCV treatment for
PWID [30] and recommendations set forth by Grebely
et al. [31]. Based on these results it appears that there is
a substantial opportunity to improve care, and corre-
sponding health outcomes, among HIV/HCV co-infected
PWID in Russia.
The finding that HCV infection was nearly universal
among these HIV-infected PWID in St. Petersburg is
consistent with prior literature. Globally, Russia has
among the highest burdens of HCV co-infection among
PWID with HIV [32]. The HIV epidemic in Russia is
primarily driven through parenteral drug use, and in this
context, the prevalence of HCV infection, which almost
invariably precedes infection with HIV, will be extremely
high to omnipresent [33]. Indeed, modeling studies sug-
gest that in countries where HIV is driven by injecting
behavior, the prevalence of HCV can be used as a meas-
ure of HIV risk [34], and Russia has a high prevalence of
HCV among PWID (50–90 %) [4, 10]. Therefore, it is
not surprising that nearly all (97–99 %) of these HIV-
infected PWID reported being told that they had HCV.
However, it is unlikely that in all cases the diagnosis was
confirmed with HCV RNA testing. Due to cost con-
straints, and the fact that patients frequently have to pay
out of pocket for these tests, HCV RNA and genotype
testing are uncommonly performed in Russia [35]. Given
that approximately 25 % of HCV-infected people will
spontaneously clear their infection [36], the true preva-
lence of current HCV infection, rather than past infec-
tion with HCV, in this sample was likely lower than
reported.
This study demonstrates a large discrepancy between
rates of testing and treatment among this population of
HIV-infected PWID, many of whom were being treated
for their opioid use disorders, which may explain their
high testing rates. It appears that efforts to test these
high risk patients for HCV infection are successful and
thorough. However, despite these high rates of HCV
Table 1 Baseline demographic characteristics of HIV-infected Russian PWID in LINC (n = 349) and Russia ARCH (n = 207)
LINC Russia ARCH Total
Characteristic No. (%) No. (%) No. (%)
Median Age (IQR) 33.8 (31–37) 33.0 (30–36) 33.5 (31–37)
Sex
Male 256 73.4 147 71.0 403 72.5
Female 93 26.6 60 29.0 153 27.5
Race
Caucasian 349 100 207 100 556 100
Other 0 0 0 0 0 0
Education
Secondary Education or lower 314 90.0 179 86.5 493 88.7
Higher education 35 10.0 28 13.5 63 11.3
Marital Status
Married or living with partner 105 30.1 96 46.4 201 36.2
Other 244 69.9 111 53.6 355 63.8
Employment
Full-time 83 23.8 69 33.3 152 27.3
Part-time 41 11.7 22 10.6 63 11.3
Disability 11 3.2 3 1.4 14 2.5
Unemployed 190 54.4 106 51.2 296 53.2
Other (includes retired, homemaker) 24 6.9 7 3.4 31 5.6
Median Monthly Income (IQR) 35000 (20000–50000) 15000 (5000–30000) 28000 (10000–40000)
Median Years Since HIV Diagnosis (IQR) 6.6 (4–12) 7.4 (4–12) 7.1 (4–12)






ART (current or past)
Yes 43 12.3 0 0 43 7.7
No 306 87.7 207 100 513 92.3
Past 12-month drug dependence n = 344
Yes 326 94.8 127 61.4 453 82.2
No 18 5.2 80 38.6 98 17.8
Past 30-day injection drug use n = 198a
Yes 183 92.4 94 45.4 277 68.4
No 15 7.6 113 54.6 128 31.6
Past 12-month alcohol dependence
Yes 138 67.0
No 68 33.0
Abbreviations: HCV hepatitis C virus, HIV human immunodeficiency virus, PWID people who inject drugs, ART antiretroviral treatment, IQR interquartile range
aAvailable on a smaller sample due to data collection error
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of these HIV-infected PWID can access treatment. In
contrast, another study not focused on HIV-infected
persons reported lower rates of HCV diagnosis in Russia
(40 %), but also low rates of treatment (< 0.1 %) [11].
Similarly, in other countries, such as the U.S., Canada,
Australia, and India, it appears that HCV testing efforts
often fall short, with many persons, including PWID,being unaware of their infection [17–19, 37–40]. The es-
timated proportion of persons treated for HCV in the
U.S. is also low, 9 % reported in a recent meta-analysis
[15], and HIV/HCV co-infected are often not referred
for treatment [41]. It may be worth questioning the ra-
tionale for such an aggressive HCV testing program,
given the limited effort to provide HCV treatment. The
potential that awareness of HCV diagnosis positively
Table 2 HCV testing among HIV-infected Russian PWID in LINC
(n = 349) and Russia ARCH (n = 207)
LINC Russia ARCH Total
Category No. (%) No. (%) No. (%)
HCV testing
Yes 345 98.9 201 97.1 546 98.2
No 2 0.6 3 1.4 5 0.9
Unknown 2 0.6 3 1.4 5 0.9
HCV Diagnosis (Physician Notified)
Yes 345 98.9 201 97.1 546 98.2
No 4 1.1 5 2.4 9 1.6
Unknown 0 0 1 0.5 1 0.2
Time since HCV diagnosis n = 345
≤ 6 months 6 1.7
6–12 months 11 3.2
≥ 12 months 328 95.1
Location of HCV testing n = 345
Prison 37 10.7
Outpatient clinic 107 31.0
Hospital inpatient 193 55.9
Needle exchange program 1 0.3
Drug treatment program 6 3.4
Family planning 2 0.6
Other 2 0.6
Abbreviations: HCV hepatitis C virus, HIV human immunodeficiency virus, PWID
people who inject drugs
Table 3 HCV Treatment among HCV/HIV-co-infected Russian
PWID in LINC (n = 345) and Russia ARCH (n = 201)
LINC Russia ARCH Total
Category No. (%) No. (%) No. (%)
HCV treatment status
Current HCV treatment 3 0.9 1 0.5 4 0.7
Past HCV treatment 5 1.4 9 4.5 14 2.6
Never treated 336 97.4 191 95.0 527 96.5
Refused to answer 1 0.3 0 0.0 1 0.2
Time of HCV treatment initiation n = 8
≤ 6 months 1 12.5
≥ 12 months 7 87.5
Was SVR achieved n = 10
Yes 5 50.0
No 2 20.0
Don’t know 3 30.0
Abbreviations: HCV hepatitis C virus, HIV human immunodeficiency virus, PWID
people who inject drugs, SVR sustained virologic response
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ale for testing; however the evidence for this impact is
mixed [38, 42, 43].
A limitation of this study is that HCV status was based
on self-report. Also, we did not specify the nature of
prior HCV testing in the questionnaire, nor ask about
confirmatory viral load or genotype testing. Given the
expense of confirmatory HCV viral load testing, it is
likely that most participants only had an antibody test.
Another limitation is that this study is based on second-
ary analysis of existing data from two other studies,
which included eligibility criteria that participants could
not be on ART. Therefore, the sample may not be fully
representative of all co-infected PWID in St. Petersburg.
The sample might potentially be biased toward patients
who are difficult to link to care. However, there were
relatively small numbers of participants who were ineli-
gible because of ART use: in LINC 1 %, and in Russia
ARCH 13 %. It is likely the sample may be potentially
biased toward younger, newly diagnosed HIV-infected
PWID with higher CD4 cell counts not meeting criteria
for treatment. Russian guidelines at the time of study
stated that ART should be initiated for any patients with
CD4 cell counts below 350 cells/mm3. At baseline, ap-
proximately half of the participants in the combined
sample had baseline counts below that threshold, and
over time we have observed that nearly one quarter of
the sample has initiated ART. Another limitation is that
we did not ask participants about specific treatments re-
ceived; therefore, we cannot be sure that the few patients
who reported being treated had actually received stand-
ard treatment (as opposed to vitamins or other supple-
ments). However, the exact wording of the question
(“Have you taken medication to treat hepatitis C, like
Interferon and Ribavirin?”) implied anti-HCV treatment
that was the standard at the time.
This study was conducted largely before the arrival of
direct-acting antiviral (DAA) therapies, when interferon
based therapies were used. Of concern is that countries
like Russia, which are transitioning from the classifica-
tion of middle to high income (and thus restricted from
generic medications), may be particularly challenged to
afford new therapies for HCV. However, the study result
speaks to a great need for treatment among co-infected
PWID in Russia, particularly given the challenge of
meeting WHO’s targets for the goal of “elimination of
viral hepatitis as a major public health threat by 2030”
[44]. Given that persons who are co-infected with HIV/
HCV are at greater risk for having progression of their
HCV-related liver disease to cirrhosis and hepatocellular
carcinoma, the need is more urgent to address treatment
in this population in order to mitigate morbidity and
avoid downstream costs [45–47]. Furthermore, treat-
ment of HCV in this PWID population holds the
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prevention”) [47–49]. Study results also indicate a need
for expanded ART as an important initial step in engage-
ment of care.
Conclusion
Among HIV-infected PWID in St. Petersburg, Russia,
nearly all persons reported having been tested and found
to have been infected with HCV, yet few (3.3 %) had ever
been treated for their HCV infection. As such, the treat-
ment chasm in the Russian HCV cascade of care among
these HIV-infected PWID points to the great need for
expanded HCV treatment in this population.
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